Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.51 |
| ▸ | LHCGR | P22888 | 6/20 | 0.49 |
| ▸ | FSHR | P23945 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5030680 | 0.93 | LHCGR (0.53) | BRAFLHCGRFSHRTSHRMAP4K4 | |
| SCHEMBL5026102 | 0.93 | LHCGR (0.53) | BRAFLHCGRFSHRTSHR | |
| SCHEMBL5024538 | 0.92 | LHCGR (0.52) | BRAFLHCGRFSHRTSHRMAP4K4 | |
| SCHEMBL5028902 | 0.91 | BRAF (0.52) | BRAFLHCGRFSHRTSHR | |
| SCHEMBL5765184 | 0.91 | BRAF (0.51) | BRAFLHCGRFSHRTSHRJAK3 | |
| SCHEMBL30673523 | 0.90 | LHCGR (0.64) | LHCGRFSHRTSHRMAP4K4JAK3 | |
| SCHEMBL5026884 | 0.90 | LHCGR (0.64) | LHCGRFSHRTSHRMAP4K4JAK3 | |
| SCHEMBL6536790 | 0.89 | LHCGR (0.46) | BRAFLHCGRFSHRTSHRMAP4K4 | |
| SCHEMBL4428981 | 0.88 | BRAF (0.53) | BRAFLHCGRFSHRTSHR | |
| SCHEMBL5024555 | 0.84 | LHCGR (0.55) | BRAFLHCGRFSHRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239854-A2 | METHOD OF TREATING OBESITY WITH A LUTEINIZING HORMONE RECEPTOR AGONIST | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-12-14 | — | — | WO | claimed |
| EP-1427733-B1 | THIENO[2,3-D]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | ORGANON NV (NL) | 2006-11-15 | — | — | EP | claimed |
| WO-2023239854-A2 | METHOD OF TREATING OBESITY WITH A LUTEINIZING HORMONE RECEPTOR AGONIST | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-12-14 | — | — | WO | disclosed |
| US-7317006-B2 | Thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity | N.V. ORGANON (NL) | 2008-01-08 | — | — | US | disclosed |
| EP-1427733-B1 | THIENO[2,3-D]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | ORGANON NV (NL) | 2006-11-15 | — | — | EP | disclosed |
| US-20040180873-A1 | Thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | MERCK SHARP & DOHME B.V. (NL) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180873-A1 | Thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | FSHR, GNRHR, LHCGR | BRAF 4516/4885LHCGR 3/4885FSHR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.